508 related articles for article (PubMed ID: 31703698)
1. Epitope-based peptide vaccine design and target site depiction against Middle East Respiratory Syndrome Coronavirus: an immune-informatics study.
Tahir Ul Qamar M; Saleem S; Ashfaq UA; Bari A; Anwar F; Alqahtani S
J Transl Med; 2019 Nov; 17(1):362. PubMed ID: 31703698
[TBL] [Abstract][Full Text] [Related]
2. Epitope-Based Vaccine Target Screening against Highly Pathogenic MERS-CoV: An In Silico Approach Applied to Emerging Infectious Diseases.
Shi J; Zhang J; Li S; Sun J; Teng Y; Wu M; Li J; Li Y; Hu N; Wang H; Hu Y
PLoS One; 2015; 10(12):e0144475. PubMed ID: 26641892
[TBL] [Abstract][Full Text] [Related]
3. Reverse vaccinology assisted designing of multiepitope-based subunit vaccine against SARS-CoV-2.
Tahir Ul Qamar M; Shahid F; Aslam S; Ashfaq UA; Aslam S; Fatima I; Fareed MM; Zohaib A; Chen LL
Infect Dis Poverty; 2020 Sep; 9(1):132. PubMed ID: 32938504
[TBL] [Abstract][Full Text] [Related]
4. Immunoinformatics-guided design of an epitope-based vaccine against severe acute respiratory syndrome coronavirus 2 spike glycoprotein.
Rakib A; Sami SA; Mimi NJ; Chowdhury MM; Eva TA; Nainu F; Paul A; Shahriar A; Tareq AM; Emon NU; Chakraborty S; Shil S; Mily SJ; Ben Hadda T; Almalki FA; Emran TB
Comput Biol Med; 2020 Sep; 124():103967. PubMed ID: 32828069
[TBL] [Abstract][Full Text] [Related]
5. Recombinant Receptor-Binding Domains of Multiple Middle East Respiratory Syndrome Coronaviruses (MERS-CoVs) Induce Cross-Neutralizing Antibodies against Divergent Human and Camel MERS-CoVs and Antibody Escape Mutants.
Tai W; Wang Y; Fett CA; Zhao G; Li F; Perlman S; Jiang S; Zhou Y; Du L
J Virol; 2017 Jan; 91(1):. PubMed ID: 27795425
[TBL] [Abstract][Full Text] [Related]
6. Exploring the out of sight antigens of SARS-CoV-2 to design a candidate multi-epitope vaccine by utilizing immunoinformatics approaches.
Safavi A; Kefayat A; Mahdevar E; Abiri A; Ghahremani F
Vaccine; 2020 Nov; 38(48):7612-7628. PubMed ID: 33082015
[TBL] [Abstract][Full Text] [Related]
7. A Highly Immunogenic and Protective Middle East Respiratory Syndrome Coronavirus Vaccine Based on a Recombinant Measles Virus Vaccine Platform.
Malczyk AH; Kupke A; Prüfer S; Scheuplein VA; Hutzler S; Kreuz D; Beissert T; Bauer S; Hubich-Rau S; Tondera C; Eldin HS; Schmidt J; Vergara-Alert J; Süzer Y; Seifried J; Hanschmann KM; Kalinke U; Herold S; Sahin U; Cichutek K; Waibler Z; Eickmann M; Becker S; Mühlebach MD
J Virol; 2015 Nov; 89(22):11654-67. PubMed ID: 26355094
[TBL] [Abstract][Full Text] [Related]
8. Antibodies and vaccines against Middle East respiratory syndrome coronavirus.
Xu J; Jia W; Wang P; Zhang S; Shi X; Wang X; Zhang L
Emerg Microbes Infect; 2019; 8(1):841-856. PubMed ID: 31169078
[TBL] [Abstract][Full Text] [Related]
9. Effect of Fc Fusion on Folding and Immunogenicity of Middle East Respiratory Syndrome Coronavirus Spike Protein.
Chun J; Cho Y; Park KH; Choi H; Cho H; Lee HJ; Jang H; Kim KH; Oh YK; Kim YB
J Microbiol Biotechnol; 2019 May; 29(5):813-819. PubMed ID: 30982320
[TBL] [Abstract][Full Text] [Related]
10. CD8+ T Cells Responding to the Middle East Respiratory Syndrome Coronavirus Nucleocapsid Protein Delivered by Vaccinia Virus MVA in Mice.
Veit S; Jany S; Fux R; Sutter G; Volz A
Viruses; 2018 Dec; 10(12):. PubMed ID: 30558354
[TBL] [Abstract][Full Text] [Related]
11. A Highly Immunogenic, Protective, and Safe Adenovirus-Based Vaccine Expressing Middle East Respiratory Syndrome Coronavirus S1-CD40L Fusion Protein in a Transgenic Human Dipeptidyl Peptidase 4 Mouse Model.
Hashem AM; Algaissi A; Agrawal AS; Al-Amri SS; Alhabbab RY; Sohrab SS; S Almasoud A; Alharbi NK; Peng BH; Russell M; Li X; Tseng CK
J Infect Dis; 2019 Oct; 220(10):1558-1567. PubMed ID: 30911758
[TBL] [Abstract][Full Text] [Related]
12. MERS-CoV spike protein: Targets for vaccines and therapeutics.
Wang Q; Wong G; Lu G; Yan J; Gao GF
Antiviral Res; 2016 Sep; 133():165-77. PubMed ID: 27468951
[TBL] [Abstract][Full Text] [Related]
13. Receptor-binding domain-based subunit vaccines against MERS-CoV.
Zhang N; Tang J; Lu L; Jiang S; Du L
Virus Res; 2015 Apr; 202():151-9. PubMed ID: 25445336
[TBL] [Abstract][Full Text] [Related]
14. The recombinant N-terminal domain of spike proteins is a potential vaccine against Middle East respiratory syndrome coronavirus (MERS-CoV) infection.
Jiaming L; Yanfeng Y; Yao D; Yawei H; Linlin B; Baoying H; Jinghua Y; Gao GF; Chuan Q; Wenjie T
Vaccine; 2017 Jan; 35(1):10-18. PubMed ID: 27899228
[TBL] [Abstract][Full Text] [Related]
15. MERS virus spike protein HTL-epitopes selection and multi-epitope vaccine design using computational biology.
Joshi A; Akhtar N; Sharma NR; Kaushik V; Borkotoky S
J Biomol Struct Dyn; 2023; 41(22):12464-12479. PubMed ID: 36935104
[TBL] [Abstract][Full Text] [Related]
16. Towards a solution to MERS: protective human monoclonal antibodies targeting different domains and functions of the MERS-coronavirus spike glycoprotein.
Widjaja I; Wang C; van Haperen R; Gutiérrez-Álvarez J; van Dieren B; Okba NMA; Raj VS; Li W; Fernandez-Delgado R; Grosveld F; van Kuppeveld FJM; Haagmans BL; Enjuanes L; Drabek D; Bosch BJ
Emerg Microbes Infect; 2019; 8(1):516-530. PubMed ID: 30938227
[TBL] [Abstract][Full Text] [Related]
17. Importance of Neutralizing Monoclonal Antibodies Targeting Multiple Antigenic Sites on the Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein To Avoid Neutralization Escape.
Wang L; Shi W; Chappell JD; Joyce MG; Zhang Y; Kanekiyo M; Becker MM; van Doremalen N; Fischer R; Wang N; Corbett KS; Choe M; Mason RD; Van Galen JG; Zhou T; Saunders KO; Tatti KM; Haynes LM; Kwong PD; Modjarrad K; Kong WP; McLellan JS; Denison MR; Munster VJ; Mascola JR; Graham BS
J Virol; 2018 May; 92(10):. PubMed ID: 29514901
[TBL] [Abstract][Full Text] [Related]
18. [Bioinformatics-based Design of Peptide Vaccine Candidates Targeting Spike Protein of MERS-CoV and Immunity analysis in Mice].
Lan J; Lu S; Deng Y; Wen B; Chen H; Wang W; Tan W
Bing Du Xue Bao; 2016 Jan; 32(1):77-81. PubMed ID: 27295887
[TBL] [Abstract][Full Text] [Related]
19. Heterologous prime-boost vaccination with adenoviral vector and protein nanoparticles induces both Th1 and Th2 responses against Middle East respiratory syndrome coronavirus.
Jung SY; Kang KW; Lee EY; Seo DW; Kim HL; Kim H; Kwon T; Park HL; Kim H; Lee SM; Nam JH
Vaccine; 2018 Jun; 36(24):3468-3476. PubMed ID: 29739720
[TBL] [Abstract][Full Text] [Related]
20. A Novel Nanobody Targeting Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Receptor-Binding Domain Has Potent Cross-Neutralizing Activity and Protective Efficacy against MERS-CoV.
Zhao G; He L; Sun S; Qiu H; Tai W; Chen J; Li J; Chen Y; Guo Y; Wang Y; Shang J; Ji K; Fan R; Du E; Jiang S; Li F; Du L; Zhou Y
J Virol; 2018 Sep; 92(18):. PubMed ID: 29950421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
